M1002 is a hypoxia-inducible factor-2 ( HIF-2 ) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors. In Vitro M1002 (10 μM; 24 h) enhances the expression of HIF-2 target genes with great efficacy. M1002 (5 μM; 24 h) treatment shows synergy with prolyl hydroxylase domain (PHD) inhibitors. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: 786-O cells Concentration: 10 μM Incubation Time: 24 hours Result: Showed clear agonistic effects on the expression of HIF-2 target genes in 786-O cells as compared with the control. RT-PCRCell Line: Hep3B cells Concentration: 5 μM Incubation Time: 24 hours Result: Elevated the expression of EPO and NDRG1 by co-treatment of M1002 together with PHD inhibitors, compared with M1002 alone treatment. Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
M1002
CAS number：823830-85-9 molecular formula：C15H8F6N2O2S
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 823830-85-9 | molecular formula | C15H8F6N2O2S |
| molecular weight | 394.29 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
